Since over 50% of men on long-term ADT will develop metabolic syndrome during their treatment, dietary therapy and low-protein intake may support the management of advanced prostate cancer through reductions of IGF-1 levels [41, 44]. This evidence concerns the gene IGF1 and prostate cancer.